GOODWILL AND OTHER INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

GOODWILL AND OTHER INTANGIBLE ASSETS

Dollars in Millions	Estimated Useful Lives	March 31, 2020			December 31, 2019
Goodwill(a)		$	22,452		$	22,488
Other intangible assets:
Licenses	5 – 15 years	482			482
Acquired developed product rights	3 – 15 years	50,427			46,827
Capitalized software	3 – 10 years	1,263			1,297
IPRD		15,900			19,500
Gross other intangible assets		68,072			68,106
Less accumulated amortization		(6,406		)	(4,137		)
Other intangible assets		$	61,666		$	63,969

(a) Includes measurement period adjustments. Refer to “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for more information.

In March 2020, $3.6 billion of IPRD was reclassified to acquired developed product rights upon approval of Zeposia in the U.S. In April 2020, the FDA approved Reblozyl to treat Anemia in adults with lower-risk MDS. As a result, $7.5 billion of IPRD will be reclassed to acquired developed products rights in the second quarter of 2020. Amortization expense of other intangible assets was $2.3 billion and $53 million for the three months ended March 31, 2020 and 2019, respectively.